Community curated by people like you

STAT News stories

Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources

00

Top claims

▪The weight loss and blood sugar reduction results from the retatrutide-Ozempic diabetes trial reported by STAT News were based on analyses of trial participants who stayed on treatment rather than all participants
▪Eli Lilly is conducting another late-stage study testing retatrutide against tirzepatide, the active ingredient in Zepbound, among adults with obesity with or without type 2 diabetes
▪Eli Lilly plans to seek regulatory approval for retatrutide in the United States in 2027

Topics

Eli Lilly Zepbound GLP-1 receptor agonists Weight management Blood sugar & insulin Weight loss drugs Retatrutide Clinical trials Novo Nordisk

Related entities

United States Tirzepatide Ozempic